对可切除食道状细胞癌的新辅助化学免疫疗法和新辅助化学疗法的比较:一项回顾性研究,使用3年生存分析
Peiyuan Wang1,2,3, Yujie Chen1, Mengxia Lei4
1Department of Thoracic Oncology Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350014, China.
Journal of cancer research and clinical oncology
|October 25, 2024
概括
与单独的化疗相比,新辅助化疗免疫疗法 (nCIT) 显著改善了食道癌患者的病理反应和3年生存率. 对于这种本地发病的长期结果,需要进一步验证.
科学领域:
- 在瘤学瘤学.
- 胃肠道手术 胃肠道手术
- 免疫治疗是一种免疫疗法.
背景情况:
- 新辅助化疗免疫疗法 (nCIT) 对局部晚期食道状细胞癌 (ESCC) 是有前途的,但长期存活数据仍然有限.
- 将nCIT与新辅助化疗 (nCT) 进行比较对于优化可切除ESCC的治疗策略至关重要.
研究的目的:
- 为了比较新辅助化学免疫疗法 (nCIT) 与新辅助化学疗法 (nCT) 在可切除,局部晚期食道状细胞癌 (ESCC) 患者的疗效.
- 评估nCIT对病理反应率,生存结果和复发模式的影响.
主要方法:
- 对ESCC患者进行nCT或nCIT并随后进行食道切除术的回顾性分析.
- 倾向分数匹配 (PSM) 用于为nCT和nCIT组创建可比较的队列.
- 主要终点:无病生存率 (DFS) 和整体生存率 (OS) 在3年随访.
主要成果:
- 与nCT相比,nCIT表现出更高的病理完整响应 (pCR) 和主要病理响应 (mPR) 率,改善瘤下降阶段,以及更高的R0切除率.
- 接受nCIT治疗的患者表现出显著改善的3年DFS和OS,远程和混合复发的发病率较低.
- 在nCIT和nCT组之间,局部复发率相似;在大多数子组中观察到nCIT的好处,包括没有pCR/mPR的子组.
结论:
- 新辅助化疗免疫疗法 (nCIT) 与新辅助化疗 (nCT) 相比,在局部发达的ESCC中提供了优越的病理反应和改善的3年生存结果.
- 这些发现表明nCIT是一种有前途的治疗方法,但需要长期生存验证.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.4K
06:11Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
Published on: April 20, 2018
9.7K
相关概念视频
01:20Comparing the Survival Analysis of Two or More Groups
155
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
155
01:21Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328